Roche’s Telavant acquisition comes as the Roivant Sciences subsidiary prepares its main asset for Phase 3 testing in ulcerative colitis. The antibody drug candidate blocks a novel target for inflammation and fibrosis that’s also the focus of clinical-stage programs of other big pharma companies.
ZURICH/FRANKFURT (Reuters) -Roche on Monday said it will buy Telavant, a developer of a new treatment for inflammatory bowel diseases, for an initial $7.1 billion from U.S biotech firm Roivant Holdings and Pfizer Inc. Under the deal, which continues Roche's drive to diversify away from its aging cancer treatment business, the Swiss drugmaker will gain the right to develop, manufacture and commercialise an experimental drug known as RVT-3101, in the U.S. and Japan. New Roche CEO Thomas Schinecker
The DNA/RNA extraction market was expected to be worth US$ 1.3 billion in 2022 and US$ 1.40 billion in 2023. The DNA/RNA extraction market will grow at a CAGR of 7.4% between 2023 and 2033, reaching a value of over US$ 2.85 billion by 2033, according to Future Market Insights’ projections. The global adoption of DNA.